15th Jul 2026 14:59
GSK PLC - London-based pharmaceutical company - Completes takeover of Nuvalent Inc, a Boston, Massachusetts-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies. The total value of the acquisition is about USD10.6 billion. Net of cash acquired, GSK's total investment is about USD9.4 billion. The transaction adds three lung cancer assets to GSK's oncology portfolio, with zidesamtinib and neladalkib "considered potential best-in-class assets", and under Food & Drug Administration review for ROS1-positive and ALK-altered non-small cell lung cancer. GSK says: "Both have received FDA breakthrough therapy and orphan drug designations. If approved, they are expected to launch in 2026 with multi-blockbuster potential." Read More
